Advertisement
Australia markets closed

  • ALL ORDS

    7,837.40
    -100.10 (-1.26%)
     

  • ASX 200

    7,575.90
    -107.10 (-1.39%)
     

  • AUD/USD

    0.6550
    +0.0027 (+0.42%)
     

  • OIL

    84.00
    +0.43 (+0.51%)
     

  • GOLD

    2,351.80
    +9.30 (+0.40%)
     

  • Bitcoin AUD

    98,409.91
    +319.32 (+0.33%)
     

  • CMC Crypto 200

    1,391.20
    -5.34 (-0.38%)
     

  • AUD/EUR

    0.6099
    +0.0026 (+0.42%)
     

  • AUD/NZD

    1.0974
    +0.0016 (+0.15%)
     

  • NZX 50

    11,805.09
    -141.34 (-1.18%)
     

  • NASDAQ

    17,430.50
    -96.30 (-0.55%)
     

  • FTSE

    8,078.86
    +38.48 (+0.48%)
     

  • Dow Jones

    38,085.80
    -375.12 (-0.98%)
     

  • DAX

    17,917.28
    -171.42 (-0.95%)
     

  • Hang Seng

    17,714.09
    +429.55 (+2.49%)
     

  • NIKKEI 225

    37,934.76
    +306.28 (+0.81%)
     

Is Novavax (NVAX) Stock Outpacing Its Medical Peers This Year?

Zacks Equity Research
·2-min read

Investors focused on the Medical space have likely heard of Novavax (NVAX), but is the stock performing well in comparison to the rest of its sector peers? One simple way to answer this question is to take a look at the year-to-date performance of NVAX and the rest of the Medical group's stocks.

Novavax is a member of the Medical sector. This group includes 901 individual stocks and currently holds a Zacks Sector Rank of #9. The Zacks Sector Rank considers 16 different sector groups. The average Zacks Rank of the individual stocks within the groups is measured, and the sectors are listed from best to worst.

The Zacks Rank emphasizes earnings estimates and estimate revisions to find stocks with improving earnings outlooks. This system has a long record of success, and these stocks tend to be on track to beat the market over the next one to three months. NVAX is currently sporting a Zacks Rank of #2 (Buy).

Within the past quarter, the Zacks Consensus Estimate for NVAX's full-year earnings has moved 297.23% higher. This is a sign of improving analyst sentiment and a positive earnings outlook trend.

ADVERTISEMENT

Based on the latest available data, NVAX has gained about 4,108.54% so far this year. Meanwhile, stocks in the Medical group have gained about 1.78% on average. This means that Novavax is outperforming the sector as a whole this year.

Looking more specifically, NVAX belongs to the Medical - Biomedical and Genetics industry, which includes 393 individual stocks and currently sits at #121 in the Zacks Industry Rank. Stocks in this group have gained about 6.05% so far this year, so NVAX is performing better this group in terms of year-to-date returns.

NVAX will likely be looking to continue its solid performance, so investors interested in Medical stocks should continue to pay close attention to the company.


Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
 
Novavax, Inc. (NVAX) : Free Stock Analysis Report
 
To read this article on Zacks.com click here.
 
Zacks Investment Research